ArticleFrontiers in oncology2025
Wallerian degeneration of the corticospinal tract following multimodal high-grade glioma treatment: a case series and recommendations for radiotherapy planning.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Establishment of a machine learning prediction model for Wallerian degeneration after ischemic stroke.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Wallerian Degeneration of the Corticospinal Tract (WDCT) is a scarcely reported complication of multimodal treatment for high-grade gliomas, which, despite its potential clinical impact, may lead to severe motor dysfunction and impair quality of life. Methodology: This retrospective case series describes 13 adult patients with high-grade gliomas treated between 2018 and 2023 who developed imaging findings consistent with WDCT after receiving multimodal treatment. Clinical and radiological data were collected from medical records; a standardized imaging follow-up or functional scoring system was not applied. Tractography was retrospectively available for two cases, enabling its incorporation into radiotherapy planning system for CST precise delineation and corresponding dose estimation. Results: WDCT was identified in 13 out of 192 high-grade glioma patients (6.8%). Diagnosis was based on T2/FLAIR hyperintensity along the ipsilateral CST with compatible clinical symptoms. Three cases developed WDCT after reirradiation, and seven (53.8%) had received bevacizumab prior to diagnosis: two during disease progression, two for the treatment of radionecrosis, and three as prophylaxis. Clinical symptomatology was detailed to 11 patients, 72.7% presented with hemiparesis, and 36.4% had seizures. In two cases, retrospective dose-volume analysis revealed CST mean doses ranging from 25.81 Gy to 42.83 Gy. Conclusions: This retrospective series highlights WDCT as a potentially underrecognized complication in glioma patients undergoing multimodal treatment. While etiology is likely multifactorial, radiotherapy may play a contributing role. CST delineation, when tractography is available, may support individualized treatment planning, enable better assessment of dose exposure, and help identify patients at higher risk of motor decline. Further prospective studies are warranted to define dose thresholds and assess functional outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.